Acronym:
PISCES
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Melanoma & other skin | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Melanoma |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Both | Anticipated Start Date | 2018-06-01 |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Melanoma |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2018-06-01 |
| Anticipated End Date |
Trial Summary
A multi-centre, open-label study of intratumoral tavokinogene teleplasmid (tavo, pIL-12) plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who are progressing on either pembrolizumab or nivolumab treatment
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Calvary Central Districts Hospital | Julie Rowe | julie.rowe@calvarycare.org.au | 08 8239 9536 | Recruiting |